 |
|
|
|
 |
|
|
| Article 1 to 8 out of 8 concerning Affitech AS
|
-
Affitech signs antibody research and licensing agreement with Roche
(05/09/2007)
Affitech AS announced that they have signed a research and licensing agreement with Roche to produce fully human monoclonal antibodies against an unnamed oncology target. The agreement tasks Affitech with first using their proprietary phagemid ...
-
Positive results using Affitech-identified human antibody that blocks VEGF binding to VEGF receptor 2
(04/26/2007)
Affitech AS announced that Peregrine Pharmaceuticals, Inc. reported positive in vivo test results of R3, a fully human monoclonal antibody developed by Affitech, in a pancreatic cancer model at the recently concluded Centennial Annual Meeting of the ...
-
Affitech contracts with ProBioGen for producer cell line generation for oncology antibody candidate
(04/13/2007)
ProBioGen AG, and Affitech AS, jointly announced that they have entered into an agreement for a biopharmaceutical cell line to be developed by ProBioGen for high-level production of one of the lead candidates in Affitech's oncology therapeutic ...
-
Pharmexa and Affitech enter into an exclusive license agreement to promote Diabody technology
(04/04/2007)
Pharmexa and Affitech A/S have entered into a license agreement to promote a single chain bi-specific antibody (diabody) technology to third parties for further product development, as well as to utilize the technology for Affitech's own ...
-
Affitech signs license agreement for single-chain antibody technology with Micromet
(03/30/2007)
Affitech AS announced that it has signed an agreement with Micromet AG for a non-exclusive worldwide sub-licensable research license to the joint patent estate of Micromet and Enzon Pharmaceuticals, Inc. in the field of single-chain antibodies ...
-
Affitech to play key role in major EU embryonal tumor pipeline project
(09/14/2006)
Proprietary discovery platforms to be utilized to identify fully human therapeutic antibody candidates
Affitech announced that it has been selected to participate in the new European Union E.E.T. Pipeline project to identify fully human therapeutic antibody candidates for Embryonal Tumors (ET) by using its antibody discovery platform. The E.E.T. ...
-
Affitech renews exclusive worldwide phage display license from DKFZ
(04/11/2006)
"Breitling" patents hold key position in human antibody discovery field
Affitech AS, announced that they have renewed an exclusive worldwide licensing agreement with DKFZ (German Cancer Research Center) of Heidelberg, Germany for the antibody library display patents, otherwise known as "Breitling" IP family. These ...
-
Affitech and XOMA Sign Antibody Collaboration and Cross-License Agreement
(12/01/2005)
Affitech AS and XOMA Ltd. announced that they have signed an antibody collaboration and crosslicense agreement for antibody-related technologies. Financial terms were not disclosed. Under the agreement, Affitech receives a license to use XOMA's ...
Additional information
Affitech AS
Oslo, Norway
Company
|
|
|
|
|
|
Top
